Abstract:Objective To explore the efficacy of edaravone dexborneol in the treatment of early acute progressive atherosclerotic cerebral infarction. Methods A total of 140 patients with progressive atherosclerotic cerebral infarction who were treated in Xuzhou Central Hospital from June to September 2021, within 48 hours of onset, without intravenous thrombolysis and intravascular interventional therapy were included in the retrospective study.According to whether using edaravone dexborneol, they were divided into experimental group （n=64, used）and control group（n=76, unused）, and the effects of the two groups after 14 days of treatment were compared. Results The effective rate was 87.5% in the experimental group and 86.8% in the control group， and the difference between two groups was not statistically significant (P>0.05). There was no significant difference in baseline data, lesion location, main blood indexes, NIHSS score and mRS score between two groups before treatment （P＞0.05）. The NIHSS scores and mRS scores of the two groups after treatment were lower than those before treatment (P<0.05), but there was no significant difference between the two groups after treatment (P>0.05). Conclusion Edaravone dexborneol does not further promote the restoration of nerve function in patients with early acute progressive atherosclerotic cerebral infarction on the basis of drug treatment such as butylphthalide sodium chloride.